Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Mechanistic insights into the resistance to anti-CD38 therapy

Torben Plesner • 14 Sep 2019
IMW 2019
Multiple Myeloma Antibodies Daratumumab

Torben Plesner, MD from the University of Southern Denmark, Odense, Denmark, delivers mechanistic insights and resistance of CD38 monoclonal antibody therapy. Recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Torben Plesner

3:36
Daratumumab practical considerations in MM
Torben Plesner • 16 May 2019
2:08
Novel drug delivery method to prevent daratumumab infusion-related reactions in MM
Torben Plesner • 19 Jul 2018
3:10
The challenges of treating plasma cell leukemia
Torben Plesner • 4 May 2018
1:43
Managing plasma cell leukemia: Pls, IMiDs, alkylating agents and antibodies
Torben Plesner • 4 May 2018

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals